Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies

Next Previous
Trial Profile

Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BT 7480 (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Anal cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bicycle Therapeutics

Most Recent Events

  • 30 Oct 2025 According to a Bicycle Therapeutics media release, the data from the trial will be presented at the scientific conference in the first half of 2026.
  • 04 Feb 2025 Status changed from recruiting to active, no longer recruiting.
  • 13 Jan 2025 According to a Bicycle Therapeutics media release, company to report combination data for BT7480 plus nivolumab in 4Q 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top